Tumor-penetrating peptides

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Teesalu, Tambet ^a,b   Sugahara, Kazuki N ^a,c   Ruoslahti, Erkki ^a,d  

^a BURNHAM INSTITUTE   (United States)

^b Faculty of Medicine   (Estonia)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

v integrins; C end Rule; Homing peptide; Neuropilin 1; Synaphic targeting; Tumor penetrating peptide

Indexed keywords

CELL PENETRATING PEPTIDE; DOXORUBICIN; IRGD PEPTIDE; LYP 1 PEPTIDE; NEUROPILIN 1; PACLITAXEL; SEMAPHORIN; TRASTUZUMAB; TUFTSIN; TUMOR PENETRATING PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLOOD VESSEL PERMEABILITY; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TRANSPORT; EDEMA; HUMAN; INTERNALIZATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84891128382     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00216     Document Type: Review

References (62)

1. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 188:759-68. doi:10.1083/jcb.200910104
2. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 5:1359-64. doi:10.1038/9467
3. Akerman ME, Pilch J, Peters D, Ruoslahti E. Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A (2005) 102:2040-5. doi:10.1073/pnas.0409844102
4. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater (2012) 24:3747-56. doi:10.1002/adma.201200454
5. Girard JP, Springer TA. High endothelial venules (HEVs), specialized endothelium for lymphocyte migration. Immunol Today (1995) 16:449-57. doi:10.1016/0167-5699(95)80023-9
6. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med (2010) 51(Suppl 1):33S-7. doi:10.2967/jnumed.109.069633
7. Fogal V, Zhang L, Krajewski S, Ruoslahti E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res (2008) 68:7210-8. doi:10.1158/0008-5472.CAN-07-6752
8. Pasqualini R, Ruoslahti E. Tissue targeting with phage peptide libraries. Mol Psychiatry (1996) 1:423.
9. Teesalu T, Sugahara KN, Ruoslahti E. Mapping of vascular ZIP codes by phage display. Methods Enzymol (2012) 503:35-56. doi:10.1016/B978-0-12-396962-0.00002-1
10. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med (2002) 8:751-5.
11. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A (2004) 101:9381-6. doi:10.1073/pnas.0403317101
12. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A (2009) 106:16157-62. doi:10.1073/pnas.0908201106
13. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 16:510-20. doi:10.1016/j.ccr.2009.10.013
14. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science (1990) 249:386-90. doi:10.1126/science.1696028
15. Smith GP. Filamentous fusion phage, novel expression vectors that display cloned antigens on the virion surface. Science (1985) 228:1315-7. doi:10.1126/science.4001944
16. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem (1993) 268:20205-10.
17. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development (2002) 129:4797-806.
18. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol (2010) 188:115-30. doi:10.1083/jcb.200903137
19. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell (1997) 90:739-51. doi:10.1016/S0092-8674(00)80534-6
20. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 92:735-45. doi:10.1016/S0092-8674(00)81402-6
21. von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, et al. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J Biol Chem (2006) 281:5702-10. doi:10.1074/jbc.M511941200
22. Gerdin B, Lindeberg G, Ragnarsson U, Saldeen T, Wallin R. Structural requirements for microvascular permeability-increasing ability of peptides. Studies on analogues of a fibrinogen pentapeptide fragment. Biochim Biophys Acta (1983) 757:366-70. doi:10.1016/0304-4165(83)90063-6
23. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci U S A (2007) 104:6152-7. doi:10.1073/pnas.0700043104
24. Haspel N, Zanuy D, Nussinov R, Teesalu T, Ruoslahti E, Aleman C. Binding of a C-end rule peptide to the neuropilin-1 receptor, a molecular modeling approach. Biochemistry (2011) 50:1755-62. doi:10.1021/bi101662j
25. Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Aleman C, et al. Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor. J Struct Biol (2013) 182:78-86. doi:10.1016/j.jsb.2013.02.006
26. Getz JA, Cheneval O, Craik DJ, Daugherty PS. Design of a Cyclotide antagonist of neuropilin-1 and-2 that potently inhibits endothelial cell migration. ACS Chem Biol (2013) 8:1147-54. doi:10.1021/cb4000585
27. Uniewicz KA, Fernig DG. Neuropilins, a versatile partner of extracellular molecules that regulate development and disease. Front Biosci (2008) 13:4339-60. doi:10.2741/3008
28. Bagri A, Tessier-Lavigne M, Watts RJ. Neuropilins in tumor biology. Clin Cancer Res (2009) 15:1860-4. doi:10.1158/1078-0432.CCR-08-0563
29. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins, structure, function and role in disease. Biochem J (2008) 411:211-26. doi:10.1042/BJ20071639
30. Jia H, Bagherzadeh A, Hartzoulakis B, Jarvis A, Lohr M, Shaikh S, et al. Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J Biol Chem (2006) 281:13493-502. doi:10.1074/jbc.M512121200
31. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res (2007) 13:4759-68. doi:10.1158/1078-0432.CCR-07-0001
32. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, et al. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol (2007) 366:815-29. doi:10.1016/j.jmb.2006.11.021
33. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood (2011) 117:920-7. doi:10.1182/blood-2010-05-282921
34. Nasarre C, Roth M, Jacob L, Roth L, Koncina E, Thien A, et al. Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. Oncogene (2010) 29:2381-92. doi:10.1038/onc.2010.9
35. Skidgel RA. Bradykinin-degrading enzymes, structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol (1992) 20(Suppl 9):S4-9. doi:10.1097/00005344-199206209-00002
36. Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem (2001) 49:419-32. doi:10.1177/002215540104900401
37. Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene (2012) 31:3754-63. doi:10.1038/onc.2011.537
38. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 328:1031-5. doi:10.1126/science.1183057
39. Chambers TJ, Weir RC, Grakoui A, McCourt DW, Bazan JF, Fletterick RJ, et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci U S A (1990) 87:8898-902. doi:10.1073/pnas.87.22.8898
40. Wool-Lewis RJ, Bates P. Endoproteolytic processing of the ebola virus envelope glycoprotein, cleavage is not required for function. J Virol (1999) 73:1419-26.
41. Sjöberg M, Wallin M, Lindqvist B, Garoff H. Furin cleavage potentiates the membrane fusion-controlling intersubunit disulfide bond isomerization activity of leukemia virus Env. J Virol (2006) 80:5540-51. doi:10.1128/JVI.01851-05
42. Sanchez AJ, Vincent MJ, Erickson BR, Nichol ST. Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J Virol (2006) 80:514-25. doi:10.1128/JVI.80.1.514-525.2006
43. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence arg-X-X-arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem (1992) 267:16396-402.
44. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279:377-80. doi:10.1126/science.279.5349.377
45. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes, ligand specificities of the RGD-directed integrins. Biotechnology (N Y) (1995) 13:265-70. doi:10.1038/nbt0395-265
46. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res (2000) 60:722-7.
47. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR, more than meets the eye. Blood (2008) 112:2628-35. doi:10.1182/blood-2008-04-150862
48. Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, et al. De novo design of a tumor-penetrating peptide. Cancer Res (2013) 73:804-12. doi:10.1158/0008-5472.CAN-12-1668
49. Myrberg H, Zhang L, Mae M, Langel U. Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem (2008) 19(1):70-5. doi:10.1021/bc0701139
50. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 99:1441-54. doi:10.1093/jnci/djm135
51. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 11:8782-8. doi:10.1158/1078-0432.CCR-05-1664
52. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res (2008) 14:2171-9. doi:10.1158/1078-0432.CCR-07-4465
53. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci (2004) 25:536-42. doi:10.1016/j.tips.2004.08.008
54. Tufto I, Hansen R, Byberg D, Nygaard KHH, Tufto J, Davies CDL. The effect of collagenase and hyaluronidase on transient perfusion in human osteosarcoma xenografts grown orthotopically and in dorsal skinfold chambers. Anticancer Res (2007) 27:1475-81.
55. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (2010) 15:166-79. doi:10.2741/3613
56. Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E. Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32. Mol Ther (Forthcoming 2013).
57. Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A (2011) 108:17450-5. doi:10.1073/pnas.1114518108
58. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids (2006) 30:351-67. doi:10.1007/s00726-005-0289-3
59. Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine (2009) 5:73-82. doi:10.1016/j.nano.2008.07.007
60. Uchida M, Kosuge H, Terashima M, Willits DA, Liepold LO, Young MJ, et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano (2011) 5:2493-502. doi:10.1021/nn102863y
61. Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM, et al. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2011) 108:7154-9. doi:10.1073/pnas.1104540108
62. Zhang F, Niu G, Lin X, Jacobson O, Ma Y, Eden HS, et al. Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids (2012) 42:2343-51. doi:10.1007/s00726-011-0976-1